Sentinel Lymph Node Mapping in Esophageal Cancer Using ICG Dye and NIR Imaging

Running, not enrolling · Not applicable

Conditions studied: Esophageal Cancer

In brief

The purpose of this study is to find out whether sentinel lymph node (SLN) mapping with ICG dye and NIR imaging can be used to identify esophageal or esophagogastric junction cancer that has spread to the lymph nodes. If SLN mapping is successful in these types of cancer, surgeons in the future could identify the sentinel lymph nodes and only remove these instead of removing all the lymph nodes which is currently done.

Key facts

Study ID: NCT04400292
Run by: Memorial Sloan Kettering Cancer Center
People needed: 90
Starts: 2020-05-20
Expected to finish: 2027-05-01
Last updated by the study team: 2026-07-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Pathological diagnosis of adenocarcinoma tumor located in distal 1/3 of esophagus or esophagogastric junction , with a plan to undergo minimally invasive esophagectomy.
All patients with Stage IVA (AJCC Cancer Staging Manual, 8th edition) disease will be eligible
≥18 years of age.
Documented, signed, and dated informed consent, obtained before any procedures, for the proposed research study and for standard surgical resection.

You may not qualify if…

No plan to undergo surgical resection.
Severe iodide or seafood allergy.
Women of childbearing potential without a negative pregnancy test; or women who are lactating.
Prior diagnosis of severe hepatic or renal dysfunction.
Patients with Stage IVB or M1 disease (AJCC Cancer Staging Manual, 8th edition)
Patients with local recurrence and planning to undergo salvage esophagectomy

Where it is running

Memorial Sloan Kettering Cancer Center (All Protocol Activities) — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.